Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Weekly Wrap 28 October

Grady Wulff
October 28, 2022

Morning Bell 28 October

Sophia Mavridis
October 28, 2022

Closing Bell 27 October

Grady Wulff
October 27, 2022

Morning Bell 27 October

Grady Wulff
October 27, 2022

Closing Bell 26 October

Sophia Mavridis
October 26, 2022

Morning Bell 26 October

Sophia Mavridis
October 26, 2022

Closing Bell 25 October

Sophia Mavridis
October 25, 2022

Morning Bell 25 October

Sophia Mavridis
October 25, 2022

Closing Bell 24 October

Grady Wulff
October 24, 2022

Morning Bell 24 October

Grady Wulff
October 24, 2022

Weekly Wrap 21 October

Grady Wulff
October 21, 2022

Morning Bell 21 October

Sophia Mavridis
October 21, 2022